KHRNF / Khiron Life Sciences's Study: 80% Positively Respond To Cannabinoid Treatment For Chronic Pain And Other Conditions

Khiron Life Sciences Corp. (OTCQX:KHRNF) Q3 2022 Earnings Conference Call November 30, 2022 11:00 AM ET Company Participants Alvaro Torres - CEO and C more_horizontal

TORONTO , Nov. 18, 2022 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMXC), the glo more_horizontal

Khiron Life Sciences Corp. (OTCQX:KHRNF) Q2 2022 Earnings Conference Call August 29, 2022 10:00 AM ET Company Participants Paola Ricardo - Investor Re more_horizontal

Khiron Life Sciences Corp. (TSXV: KHRN) (OTC: KHRNF) has priced and sized its overnight marketed public offering. The company intends to issue 26.70 more_horizontal

Khiron Life Sciences Corp. (OTCQX:KHRNF) Q4 2021 Earnings Conference Call May 2, 2022 10:00 AM ET Company Participants Alvaro Torres – Chief Executi more_horizontal

TORONTO , March 7, 2022 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN)(OTCQX: KHRNF)(Frankfurt: A2JMZC), a medical more_horizontal

TORONTO , March 7, 2022 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN)(OTCQX: KHRNF)(Frankfurt: A2JMZC), a medical more_horizontal

TORONTO , March 7, 2022 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN)(OTCQX: KHRNF)(Frankfurt: A2JMZC), a medical more_horizontal